Last reviewed · How we verify
Sufentanil I
Sufentanil, marketed by Aarhus University Hospital, is an opioid analgesic with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and well-documented efficacy. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Sufentanil I |
|---|---|
| Also known as | Sufenta |
| Sponsor | Aarhus University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- COmbined pLaTelet and eRythrocyte AutotransfusioN During Cardiac surgEry (COLTRANE) Trial (NA)
- The Immune Response of Breast Cancer Patients Treated With Levobupivacaine Using Paravertebral or Superficial Chest Blocks (NA)
- The Influence of Two Different CO2 Absorbers on Sevoflurane Consumption During Anaesthesia
- Stress, Anxiety and Type A Personality and Analgesics (PHASE4)
- Monitor-Guided Analgesia During General Anesthesia - Part I (NA)
- Labor Analgesia in the Latent Phrase (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sufentanil I CI brief — competitive landscape report
- Sufentanil I updates RSS · CI watch RSS
- Aarhus University Hospital portfolio CI